Large gap with delayed quotes
|
Last quote
09/03/2025
-
21:50:14
|
Bid
09/03/2025 -
21:50:33
|
Bid Volume |
Ask
09/03/2025 -
21:50:33
|
Ask Volume |
|---|---|---|---|---|
|
4.00
-0.05
(
-1.23% )
|
4.00
|
5,200 |
4.01
|
1,600 |
Analysis date: 02.09.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 13.06.2025.
Interest
Weak
Weak
Two stars since 19.08.2025.
Earnings Rev Trend
0.10
0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 13.06.2025 at a price of 3.20.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 03.06.2025.
4wk Rel Perf
-7.33%
-7.33%
The four-week dividend-adjusted underperformance versus SP500 is 7.33%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 2.03%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.22%.
Mkt Cap in $bn
1.25
1.25
With a market capitalization <$2bn, ABCELLERA BIOLOGICS is considered a small-cap stock.
G/PE Ratio
-0.50
-0.50
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-6.84
-6.84
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-3.44%
-3.44%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
5
5
Over the last seven weeks, an average of 5 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
238
238
For 1% of index variation, the stock varies on average by 2.38%.
Correlation
0.53
0.53
52.72% of stock movements are explained by index variations.
Value at Risk
2.20
2.20
The value at risk is estimated at USD 2.20. The risk is therefore 54.31%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
26.03.2021
26.03.2021